B

Braveheart Bio

BRVEPro tracking

Braveheart Bio, Inc. · Nasdaq · Cardiovascular biotechnology · Research source · 424B4 · Research as of 2026/08/06 · Latest filing · 10-Q · 2026-11-10 SEC ↗ · SEC checked 2026-11-21

SEC
Saved research available · 424B4

Braveheart Bio priced its IPO at $18.00 per share for 21.25 million shares, with expected net proceeds of approximately $351.2 million before any overallotment exercise.

Research source · 424B4 · Research as of 2026/08/06Latest analyzed filing · 424B4 · 2026-08-06

Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.

SummaryWATCHReport source · 424B4

Newly listed — review valuation, deal quality and post-IPO supply before acting

A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. The IPO priced at $18.00 and raised $382.50M.

Full source-backed summary

A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. The IPO priced at $18.00 and raised $382.50M. The latest market-value reference is $1.77B; reported revenue is Pre-revenue and net result is $(80.23M). The offer figures are reconciled to the final prospectus.

Net loss($66,052,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Voting controlNo controlling party conclusion availableNot separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
Business and development direction

A clinical-stage developer of therapies for hypertrophic cardiomyopathy and other cardiovascular diseases.

Current business

Cardiovascular biotechnology100%

Future development

Future direction not yet disclosed

DECISION DRIVERS

Key risks

High

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

High

Risk 2

The latest reported period remains loss-making.

High

Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

NEXT EVENTFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
LATEST EVIDENCE424B42026/08/06
LISTING CHECKPOINT2026-08-06Nasdaq
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualityThis saved report has no compatible source inputs for this calculation. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1Goldman Sachs & Co. LLC27.50%5,843,750 shares
2Jefferies LLC27.50%5,843,750 shares
3TD Securities (USA) LLC20.00%4,250,000 shares
4Stifel, Nicolaus & Company, Incorporated14.00%2,975,000 shares
5Cantor Fitzgerald & Co.11.00%2,337,500 shares

Ratio = institution commitment ÷ complete source-table total (21,250,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number of Shares

Number of Shares

SEC table 34 row 8; source 2606775:2612093; SHA256 16c68bf9e004871c5a7dc3ca908634bde723f36e7047ecad2d429330d235663e

Goldman Sachs & Co. LLC: 5843750 / 21250000 × 100

Jefferies LLC: 5843750 / 21250000 × 100

TD Securities (USA) LLC: 4250000 / 21250000 × 100

Stifel, Nicolaus & Company, Incorporated: 2975000 / 21250000 × 100

Cantor Fitzgerald & Co.: 2337500 / 21250000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.26$ / share
Total underwriting discount$26,775,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 4 row 4; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 4 row 4; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

IPO CAPITAL QUALITY

Offering price $ / share$18
Gross offering amount $$382,500,000
Shares offered Shares21,250,000
Issuer proceeds before expenses $$355,725,000
Basis and evidence

No estimate is substituted for missing offer terms.

Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered21,250,000Shares
Offering price$18$ / share
Gross offering amount$382,500,000$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 9 row 2; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗
IPO investors$382.50Mgross offer size
Issuer / selling holdersSee 424Bprimary-secondary split
Reported revenuePre-revenue—
Net result$(80.23M)latest reported basis
Future supplyLock-upreview holder-specific terms

Proceeds and intended uses

Proceeds and intended uses
MeasureReported valueUnit
Issuer proceeds before expenses$355,725,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Issuer proceeds before expenses

Base prospectus offering; cover per-share and total columns

SEC table 4 row 5; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

Dilution and valuation

IPO price$18Final
Basic post-offer≈ 73.1528M
Equity value≈ $1.3168B
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 73.1528M≈ $1.3168B
Derived calculationFinalshares · $Basis and evidence 7 ↗
Post-offer shares — base/no option73,152,838—
Reported sourcePost-offer · BasesharesBasis and evidence 5 ↗
Post-offer shares — full option76,340,338—
Reported sourcePost-offer · Full optionsharesBasis and evidence 5 ↗
Shares offered21,250,000—
Reported sourcesharesBasis and evidence 3 ↗
Offering price—$18
Reported sourceFinal$/shareBasis and evidence 4 ↗
Gross offering amount—$382,500,000
Reported source$Basis and evidence 4 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 9 row 6 columns 3; share summary; label column 1; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 9 row 6 columns 3; share summary; label column 1; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

Basis and evidence 3

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 9 row 2; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

Basis and evidence 4

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

Basis and evidence 5

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $18

Exact input · Post-offer shares — base/no option: 73,152,838

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 76,340,338

SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

SEC table 9 row 6 columns 3; share summary; label column 1; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

SEC valuation primary issuer cover; source 1906:2256; SHA256 a7167e9c0729246e58bf28b50b6d05a4433c62cfb6481ffb7a98b2b41c43c9bf ↗

SEC valuation summary conditions; source 141840:145833; SHA256 b07316509b72afbff30fc7ba27083a823ad1eea7ef670b4c2da7e03d4bc078e2 ↗

SEC valuation summary conditions; source 152594:179500; SHA256 8ef18d0926827cda7549a1d2096790a2c8d836a79ef51417d38ac6e1da72b41f ↗

Basis and evidence 7

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 73,152,838 shares (or 76,340,338 shares if the underwriters exercise their option to purchase additional shares of common stock in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 73,152,838

Exact input · Offering price: $18

SEC table 4 row 3; source 6415:12145; SHA256 2b65ad2ca8cf79c1c0f71693026afbd435c3c683ee199559aed11c6ab5246563 ↗

SEC table 9 row 6 columns 3; share summary; label column 1; source 145898:152477; SHA256 28b39d93507c550c6ce73de8a221ffe4ab469ceeacd284d4c535abc2e212b8d2 ↗

SEC valuation primary issuer cover; source 1906:2256; SHA256 a7167e9c0729246e58bf28b50b6d05a4433c62cfb6481ffb7a98b2b41c43c9bf ↗

SEC valuation summary conditions; source 141840:145833; SHA256 b07316509b72afbff30fc7ba27083a823ad1eea7ef670b4c2da7e03d4bc078e2 ↗

SEC valuation summary conditions; source 152594:179500; SHA256 8ef18d0926827cda7549a1d2096790a2c8d836a79ef51417d38ac6e1da72b41f ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $18 × ≈ 73.1528M shares · Final

Implied equity value≈ $1.3168BPrice × post-offer shares
Post-offer shares≈ 73.1528MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Prior saved context

These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.

IPO price · 21.250M · $382.50M · $18.00

Latest shares outstanding · 64.17M · $1.77B · Market snapshot

Revenue reference · — · Pre-revenue · —

Net-result reference · — · $(80.23M) · Loss-making

$18 × 73,152,838 = $1,316,751,084 [summary-table-9-base-6-price, summary-table-9-base-6-post]

Exact calculation · Derived whole-issuer equity value: $1,316,751,084

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesComparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗
CONTROLLING PARTYNo controlling party conclusion available

Latest available filing

Economic
~33.1%*
As of
2026/08/06
!Review the beneficial-ownership table and voting rights togetherView source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Braveheart Bio
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
AH Bio Fund IV, L.P.Beneficial shares9,132,420——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
AH Bio Fund IV, L.P.Beneficial shares9,132,420——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Entities affiliated with ForbionBeneficial shares18,226,024——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Entities affiliated with ForbionBeneficial shares18,226,024——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial shares7,420,091——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial shares7,420,091——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Orbimed Private Investments IX, LPBeneficial shares10,235,159——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Orbimed Private Investments IX, LPBeneficial shares10,235,159——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
ES Braveheart Aggregator, L.P.Beneficial shares3,424,657——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
ES Braveheart Aggregator, L.P.Beneficial shares3,424,657——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Frazier Life Sciences Public Fund, L.P.Beneficial shares3,424,657——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Frazier Life Sciences Public Fund, L.P.Beneficial shares3,424,657——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
AH Bio Fund IV, L.P.Beneficial ownership—13.9%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
AH Bio Fund IV, L.P.Beneficial ownership—10.5%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Entities affiliated with ForbionBeneficial ownership—27.8%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Entities affiliated with ForbionBeneficial ownership—21%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial ownership—11.3%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Beneficial ownership—8.5%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Orbimed Private Investments IX, LPBeneficial ownership—15.6%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Orbimed Private Investments IX, LPBeneficial ownership—11.8%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
ES Braveheart Aggregator, L.P.Beneficial ownership—5.2%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
ES Braveheart Aggregator, L.P.Beneficial ownership—3.9%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Frazier Life Sciences Public Fund, L.P.Beneficial ownership—5.2%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Frazier Life Sciences Public Fund, L.P.Beneficial ownership—3.9%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial shares8,250,304——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial shares8,250,304——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Michele Anderson, Chief Development OfficerBeneficial shares331,050——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Michele Anderson, Chief Development OfficerBeneficial shares331,050——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
J. Paul Rickey, Chief Financial OfficerBeneficial shares675,798——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
J. Paul Rickey, Chief Financial OfficerBeneficial shares675,798——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Christopher ViehbacherBeneficial shares676,524——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Christopher ViehbacherBeneficial shares676,524——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Jason Coloma, Ph.D., M.B.A.Beneficial shares1,100,456——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
Jason Coloma, Ph.D., M.B.A.Beneficial shares1,100,456——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
David Malek, M.B.A.Beneficial shares1,009,131——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
David Malek, M.B.A.Beneficial shares1,009,131——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial ownership—12.6%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Travis Murdoch, M.D., Chief Executive Officer, President and DirectorBeneficial ownership—9.5%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Michele Anderson, Chief Development OfficerBeneficial ownership—0.4%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
J. Paul Rickey, Chief Financial OfficerBeneficial ownership—1%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
J. Paul Rickey, Chief Financial OfficerBeneficial ownership—0.8%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Christopher ViehbacherBeneficial ownership—1%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Christopher ViehbacherBeneficial ownership—0.8%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Jason Coloma, Ph.D., M.B.A.Beneficial ownership—1.7%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
Jason Coloma, Ph.D., M.B.A.Beneficial ownership—1.3%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
David Malek, M.B.A.Beneficial ownership—1.5%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
David Malek, M.B.A.Beneficial ownership—1.2%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial ownership—18.4%Beneficial—
Before Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial shares12,043,263——
Before Offering; Number of Shares of Common Stock Beneficially OwnedDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial shares12,043,263——
After Offering; Number of Shares Beneficially OwnedDisclosedEvidence
All executive officers and directors as a group (10 persons)Beneficial ownership—13.9%Beneficial—
After Offering; Percentage of Shares Beneficially OwnedDisclosedEvidence
our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliatesOwnership as disclosed—approximately 73.6%Beneficial—
Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be grante; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential p; not an additive ownership partitionDisclosedEvidence
Entities affiliated with ForbionOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
HengruiOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicableDisclosedEvidence
Source and calculation ↗
AH Bio Fund IV, L.P. · AH Bio Fund IV, L.P. — Beneficial shares · 9,132,420

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)

0001628280-26-054354 · SEC table 33 row 5 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

AH Bio Fund IV, L.P. · AH Bio Fund IV, L.P. — Beneficial shares · 9,132,420

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)

0001628280-26-054354 · SEC table 33 row 5 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Entities affiliated with Forbion · Entities affiliated with Forbion — Beneficial shares · 18,226,024

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Entities affiliated with Forbion(2)

0001628280-26-054354 · SEC table 33 row 6 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Entities affiliated with Forbion · Entities affiliated with Forbion — Beneficial shares · 18,226,024

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)

0001628280-26-054354 · SEC table 33 row 6 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Jiangsu Hengrui Pharmaceuticals Co., Ltd. — Beneficial shares · 7,420,091

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)

0001628280-26-054354 · SEC table 33 row 7 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Jiangsu Hengrui Pharmaceuticals Co., Ltd. — Beneficial shares · 7,420,091

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)

0001628280-26-054354 · SEC table 33 row 7 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Orbimed Private Investments IX, LP · Orbimed Private Investments IX, LP — Beneficial shares · 10,235,159

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)

0001628280-26-054354 · SEC table 33 row 8 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Orbimed Private Investments IX, LP · Orbimed Private Investments IX, LP — Beneficial shares · 10,235,159

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)

0001628280-26-054354 · SEC table 33 row 8 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

ES Braveheart Aggregator, L.P. · ES Braveheart Aggregator, L.P. — Beneficial shares · 3,424,657

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)

0001628280-26-054354 · SEC table 33 row 9 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

ES Braveheart Aggregator, L.P. · ES Braveheart Aggregator, L.P. — Beneficial shares · 3,424,657

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)

0001628280-26-054354 · SEC table 33 row 9 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Frazier Life Sciences Public Fund, L.P. · Frazier Life Sciences Public Fund, L.P. — Beneficial shares · 3,424,657

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)

0001628280-26-054354 · SEC table 33 row 10 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Frazier Life Sciences Public Fund, L.P. · Frazier Life Sciences Public Fund, L.P. — Beneficial shares · 3,424,657

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)

0001628280-26-054354 · SEC table 33 row 10 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

AH Bio Fund IV, L.P. · AH Bio Fund IV, L.P. — Beneficial ownership · 13.9%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)

0001628280-26-054354 · SEC table 33 row 5 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

AH Bio Fund IV, L.P. · AH Bio Fund IV, L.P. — Beneficial ownership · 10.5%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: AH Bio Fund IV, L.P.(1)

0001628280-26-054354 · SEC table 33 row 5 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Entities affiliated with Forbion · Entities affiliated with Forbion — Beneficial ownership · 27.8%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)

0001628280-26-054354 · SEC table 33 row 6 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Entities affiliated with Forbion · Entities affiliated with Forbion — Beneficial ownership · 21%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Entities affiliated with Forbion(2)

0001628280-26-054354 · SEC table 33 row 6 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Jiangsu Hengrui Pharmaceuticals Co., Ltd. — Beneficial ownership · 11.3%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)

0001628280-26-054354 · SEC table 33 row 7 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. · Jiangsu Hengrui Pharmaceuticals Co., Ltd. — Beneficial ownership · 8.5%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Jiangsu Hengrui Pharmaceuticals Co., Ltd.(3)

0001628280-26-054354 · SEC table 33 row 7 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Orbimed Private Investments IX, LP · Orbimed Private Investments IX, LP — Beneficial ownership · 15.6%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)

0001628280-26-054354 · SEC table 33 row 8 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Orbimed Private Investments IX, LP · Orbimed Private Investments IX, LP — Beneficial ownership · 11.8%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Orbimed Private Investments IX, LP(4)

0001628280-26-054354 · SEC table 33 row 8 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

ES Braveheart Aggregator, L.P. · ES Braveheart Aggregator, L.P. — Beneficial ownership · 5.2%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)

0001628280-26-054354 · SEC table 33 row 9 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

ES Braveheart Aggregator, L.P. · ES Braveheart Aggregator, L.P. — Beneficial ownership · 3.9%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: ES Braveheart Aggregator, L.P.(5)

0001628280-26-054354 · SEC table 33 row 9 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Frazier Life Sciences Public Fund, L.P. · Frazier Life Sciences Public Fund, L.P. — Beneficial ownership · 5.2%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)

0001628280-26-054354 · SEC table 33 row 10 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Frazier Life Sciences Public Fund, L.P. · Frazier Life Sciences Public Fund, L.P. — Beneficial ownership · 3.9%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Frazier Life Sciences Public Fund, L.P.(6)

0001628280-26-054354 · SEC table 33 row 10 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Travis Murdoch, M.D., Chief Executive Officer, President and Director · Travis Murdoch, M.D., Chief Executive Officer, President and Director — Beneficial shares · 8,250,304

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)

0001628280-26-054354 · SEC table 33 row 12 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Travis Murdoch, M.D., Chief Executive Officer, President and Director · Travis Murdoch, M.D., Chief Executive Officer, President and Director — Beneficial shares · 8,250,304

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)

0001628280-26-054354 · SEC table 33 row 12 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Michele Anderson, Chief Development Officer · Michele Anderson, Chief Development Officer — Beneficial shares · 331,050

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)

0001628280-26-054354 · SEC table 33 row 13 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Michele Anderson, Chief Development Officer · Michele Anderson, Chief Development Officer — Beneficial shares · 331,050

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)

0001628280-26-054354 · SEC table 33 row 13 columns 8; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

J. Paul Rickey, Chief Financial Officer · J. Paul Rickey, Chief Financial Officer — Beneficial shares · 675,798

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)

0001628280-26-054354 · SEC table 33 row 14 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

J. Paul Rickey, Chief Financial Officer · J. Paul Rickey, Chief Financial Officer — Beneficial shares · 675,798

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)

0001628280-26-054354 · SEC table 33 row 14 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Christopher Viehbacher · Christopher Viehbacher — Beneficial shares · 676,524

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Christopher Viehbacher(10)

0001628280-26-054354 · SEC table 33 row 15 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Christopher Viehbacher · Christopher Viehbacher — Beneficial shares · 676,524

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)

0001628280-26-054354 · SEC table 33 row 15 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Jason Coloma, Ph.D., M.B.A. · Jason Coloma, Ph.D., M.B.A. — Beneficial shares · 1,100,456

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)

0001628280-26-054354 · SEC table 33 row 18 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

Jason Coloma, Ph.D., M.B.A. · Jason Coloma, Ph.D., M.B.A. — Beneficial shares · 1,100,456

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)

0001628280-26-054354 · SEC table 33 row 18 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

David Malek, M.B.A. · David Malek, M.B.A. — Beneficial shares · 1,009,131

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: David Malek, M.B.A.(12)

0001628280-26-054354 · SEC table 33 row 21 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

David Malek, M.B.A. · David Malek, M.B.A. — Beneficial shares · 1,009,131

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)

0001628280-26-054354 · SEC table 33 row 21 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

Travis Murdoch, M.D., Chief Executive Officer, President and Director · Travis Murdoch, M.D., Chief Executive Officer, President and Director — Beneficial ownership · 12.6%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)

0001628280-26-054354 · SEC table 33 row 12 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Travis Murdoch, M.D., Chief Executive Officer, President and Director · Travis Murdoch, M.D., Chief Executive Officer, President and Director — Beneficial ownership · 9.5%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Travis Murdoch, M.D., Chief Executive Officer, President and Director(7)

0001628280-26-054354 · SEC table 33 row 12 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Michele Anderson, Chief Development Officer · Michele Anderson, Chief Development Officer — Beneficial ownership · 0.4%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Michele Anderson, Chief Development Officer(8)

0001628280-26-054354 · SEC table 33 row 13 columns 11,12; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

J. Paul Rickey, Chief Financial Officer · J. Paul Rickey, Chief Financial Officer — Beneficial ownership · 1%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)

0001628280-26-054354 · SEC table 33 row 14 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

J. Paul Rickey, Chief Financial Officer · J. Paul Rickey, Chief Financial Officer — Beneficial ownership · 0.8%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: J. Paul Rickey, Chief Financial Officer(9)

0001628280-26-054354 · SEC table 33 row 14 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Christopher Viehbacher · Christopher Viehbacher — Beneficial ownership · 1%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)

0001628280-26-054354 · SEC table 33 row 15 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Christopher Viehbacher · Christopher Viehbacher — Beneficial ownership · 0.8%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Christopher Viehbacher(10)

0001628280-26-054354 · SEC table 33 row 15 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

Jason Coloma, Ph.D., M.B.A. · Jason Coloma, Ph.D., M.B.A. — Beneficial ownership · 1.7%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)

0001628280-26-054354 · SEC table 33 row 18 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

Jason Coloma, Ph.D., M.B.A. · Jason Coloma, Ph.D., M.B.A. — Beneficial ownership · 1.3%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: Jason Coloma, Ph.D., M.B.A.(11)

0001628280-26-054354 · SEC table 33 row 18 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

David Malek, M.B.A. · David Malek, M.B.A. — Beneficial ownership · 1.5%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)

0001628280-26-054354 · SEC table 33 row 21 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

David Malek, M.B.A. · David Malek, M.B.A. — Beneficial ownership · 1.2%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: David Malek, M.B.A.(12)

0001628280-26-054354 · SEC table 33 row 21 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial ownership · 18.4%

Exact source ownership column: Before Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Percentage of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)

0001628280-26-054354 · SEC table 33 row 22 columns 6,7; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:5 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial shares · 12,043,263

Exact source ownership column: Before Offering; Number of Shares of Common Stock Beneficially Owned; holders may overlap; not an additive partition

Raw source column: Before Offering; Number of Shares of Common Stock Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)

0001628280-26-054354 · SEC table 33 row 22 columns 3; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:3,3:3 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial shares · 12,043,263

Exact source ownership column: After Offering; Number of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Number of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)

0001628280-26-054354 · SEC table 33 row 22 columns 9; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:7 ↗

All executive officers and directors as a group (10 persons) · All executive officers and directors as a group (10 persons) — Beneficial ownership · 13.9%

Exact source ownership column: After Offering; Percentage of Shares Beneficially Owned; holders may overlap; not an additive partition

Raw source column: After Offering; Percentage of Shares Beneficially Owned; source holder: All executive officers and directors as a group (10 persons)(13)

0001628280-26-054354 · SEC table 33 row 22 columns 12,13; source 2412312:2456309; SHA256 62440c3aca860cd9dcdb3ec681189769eb9914f20b79cd65576d29c54e7b1fb3; ownership header cells 2:5,3:9 ↗

our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates · our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates — Ownership as disclosed · approximately 73.6%

Source statement; approximately ; source predicate: will beneficially own; primary source clause; source condition: assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be grante; source scope: of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential p; not an additive ownership partition

Following the completion of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates will beneficially own approximately 73.6% of our outstanding common stock (assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options and without giving effect to (i) any potential purchases by such persons in this offering or (ii) issuance of options to be granted to certain of our employees and non-employee directors upon pricing of this offering). As a result, these persons, acting together, would be able to control all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions.

0001628280-26-054354 · SEC ownership paragraph; source 885561:886626; SHA256 4ef5e4a10ba6b46ac93d1acd3c0a3e1f48da9b7e249c52a3837809a0ef2466d1 ↗

Entities affiliated with Forbion · Entities affiliated with Forbion — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially own; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

(3)Consists of 40,000,000 shares of Series A preferred stock held by Forbion Growth Opportunities Fund III Coöperatief U.A. and 35,000,000 shares of Series A preferred stock held by Forbion Ventures Fund VII Coöperatief U.A. Entities affiliated with Forbion beneficially own more than 5% of our outstanding capital stock.

0001628280-26-054354 · SEC ownership paragraph; source 2371728:2372388; SHA256 df1c57ef2954be4b569ddcc10a114c51c927f8c100781161bf2833d893a2a2d1 ↗

Hengrui · Hengrui — Ownership as disclosed · >5%

Source statement; >; source predicate: beneficially owns; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

In September 2025, we entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”). Pursuant to the terms of the Exclusive License Agreement, Hengrui received an upfront payment of $58.2 million, comprised of $32.5 million in cash and 32,500,000 shares of non-voting Series A preferred stock with an aggregate estimated fair value of $25.7 million. A technology transfer milestone under the Exclusive License Agreement was completed in December 2025, which resulted in an accrual of $3.0 million as of December 31, 2025, which was paid as of March 31, 2026. A manufacturing technology transfer milestone under the Exclusive License Agreement was completed in March 2026, which resulted in accounts payable of $6.0 million as of March 31, 2026, which was paid in May 2026. Hengrui beneficially owns more than 5% of our outstanding capital stock. See the section titled “Business—Hengrui License Agreement” for additional information.

0001628280-26-054354 · SEC ownership paragraph; source 2378187:2379688; SHA256 3045a61a083d4a20d496cc1f8dc89c020aa03510232cf260d42e6e71963c371c ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section applies at the stated completion/consummation stage of this offering; certificate/bylaw effectiveness conditions remain applicable

Except as otherwise expressly provided in our second amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, including for the election of directors. Source context: The following description of our capital stock and certain provisions of our second amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the second amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.

0001628280-26-054354 · SEC ownership excerpt; source 2479724:2480379; SHA256 0d62337f18e4079552bc3cd9de12545c4f5dd80390aae7658fddfc791c1fc0bd; context source 2477420:2478414; SHA256 fd84189ae742af5cbe3419dfa1214ab8c1ce584b97ea8aeef28f9e50d8915c4e ↗

Saved control snapshot

The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.

Saved control snapshot
Holder / measureSharesOwnershipVoting rightsReference
Existing holdersMajor ownership group—~66.9%*—
2026/08/06Latest available filing424B4 ↗
Other disclosed classesMajor ownership group—See filing—
2026/08/06Latest available filing424B4 ↗
IPO sharesPublic / new investors—21.250M—
2026/08/06Latest available filing424B4 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

POTENTIAL SUPPLY PRESSURERequires holder-level review

IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.

Initial float
21.250M
Restricted / potential supply
64.17M
Multiple
See filing
Increase
See filing

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
The company and its officers, directors, and holders of substantially all of the company’s common stockAfter date of this prospectus · Source conditions apply180 days
Source and calculation
The company and its officers, directors, and holders of substantially all of the company’s common stock

The company and its officers, directors, and holders of substantially all of the company’s common stock have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock (collectively, the "Lock-Up Securities") during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of the representatives. See “Shares Eligible for Future Sale” for a discussion of certain transfer restrictions.

SEC lock-up paragraph; source 2619937:2621019; SHA256 c7a9c6d4e03546b51462e0ed4d40f553784215bf3ed284b47d8b22f932db8ffc ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
Over-allotment windowPost-listing See filing · Additional shares only if exercisedOver-allotment window · Additional shares only if exercised
Insider resale eligibilityHolder-specific See 424B · Existing-holder supplyInsider resale eligibility · Existing-holder supply
Basis and evidence
Over-allotment window

Over-allotment window · Additional shares only if exercised

Lock-up / shares eligible for future sale ↗
Insider resale eligibility

Insider resale eligibility · Existing-holder supply

Lock-up / shares eligible for future sale ↗

Financial quality

Financial quality
CalculationReported value
Cash and cash equivalents2025-12-31$89,161,000
Current assets2025-12-31$89,280,000
Total assets2025-12-31$89,350,000
Current liabilities2025-12-31$5,242,000
Total liabilities2025-12-31$5,333,000
Total equity / (deficit)2025-12-31($65,872,000)
Net income / (loss)FY2025($66,052,000)
Cash and cash equivalents2026-03-31 · Unaudited$80,576,000
Cash and cash equivalents2025-12-31 · Unaudited$89,161,000
Current assets2026-03-31 · Unaudited$81,072,000
Current assets2025-12-31 · Unaudited$89,280,000
Total assets2026-03-31 · Unaudited$81,878,000
Total assets2025-12-31 · Unaudited$89,350,000
Current liabilities2026-03-31 · Unaudited$10,002,000
Current liabilities2025-12-31 · Unaudited$5,242,000
Total liabilities2026-03-31 · Unaudited$10,385,000
Total liabilities2025-12-31 · Unaudited$5,333,000
Total equity / (deficit)2026-03-31 · Unaudited($78,392,000)
Total equity / (deficit)2025-12-31 · Unaudited($65,872,000)
Net income / (loss)3M ended 2026-03-31 · Unaudited($14,280,000)
Net income / (loss)3M ended 2025-03-31 · Unaudited($99,000)
Basis and evidence
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Net loss
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Net loss
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net loss
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Saved snapshot — period not verified

These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.

Financial quality

Financial quality
CalculationReported value
RevenuePre-revenue
Net resultLatest reported$(80.23M)
Market-value referencePost-listing snapshot$1.77B
Shares outstandingLatest reported64.17M
Offer size21.250M$382.50M
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Financial reviewReported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗
Evidence 01Final prospectus source verified

Why it mattersChanges dilution, public float and potential supply.

Evidence · 424B4 · 2026/08/06
Evidence 02Trading began on 2026-08-06 at $18.00

Why it mattersChanges valuation, proceeds and first-day return assumptions.

Evidence · 424B4 · 2026/08/06
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.
2026/08/06
424B4

• Final prospectus source verified

• Trading began on 2026-08-06 at $18.00

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

Potential impact
High
Risk 4

Option exercise, employee equity and lock-up expiry can expand tradable supply.

Potential impact
Medium
Document424B4SEC source document
Filed2026-08-06SEC EDGAR
Research as of2026/08/061 public filings identified
Source-bound table inputs85SEC EDGAR
Open filing ↗
Sources and calculation notes

Final prospectus, offer price, listing date and headline financial evidence reconciled

View the filing's actual first page
Braveheart Bio, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR